THE Swiss multinational Novartis and the Indian Patent Office are in the news again, as is Section 3(d) of India's Patent Act. Under the 3(d) provision, the Patent Office struck down the Novartis patent on Vymada, a heart failure drug, for lacking either novelty or an inventive step. Vymada, internationally marketed as Entresto, is a combination of two drugs: sacubitril and valsartan, and Novartis was claiming that by mixing the two, it created a "supramolecular complex", a claim rejected by the Indian Patent Office.